Eli Lilly Alzheimers Drug Fails Major Test Trial A drug developed by Eli Lilly to treat patients with Alzheimers disease symptoms failed a closely watched clinical trial. WSJs Jeanne Whalen explains the impact of the failure on Eli Lilly stock and the rest of the pharmaceutical sector which had rested its hopes on the success of the drug. Photo: Kris Tripplaar/Sipa USA
Takeda agreed to fork over $8 million initially to Resolve as the startup works toward the start of first human studies in 2013 for the lead compound, RSLV-132, a nuclease Fc fusion protein. The deal includes backup compounds as well. And if planned Phase 1b/2a work for the front runner goes as hoped, Takeda could use its exclusive option from the deal and take over global development and commercialization of the compound, leading to up to $247 million in development payments to Resolve.
Eli Lilly offers app for people with diabetes using once-per-week medication Trulicity Eli Lilly and Company has developed an app for people living with Type II diabetes who use Trulicity, the company's once-per-week injectable diabetes medication that also works with a click-activated pen. The app, which has been fully functionally ... http://www.mobihealthnews.com/content/eli-lilly-offers-app-people-diabetes-using-once-week-medication-trulicity